camlipixant   Click here for help

GtoPdb Ligand ID: 11232

Synonyms: BLU-5937 | BLU5937 | NEO5937 | P2X3 antagonist 34
PDB Ligand
Compound class: Synthetic organic
Comment: Camlipixant (BLU-5937) is a clinical stage selective P2X3 antagonist [2]. It was designed and developed by Bellus/GlaxoSmithKline, as a competitor to Merck's P2X3 inhibitor gefapixant. Cryo-electron microscopy revealed that P2X3 selectivity is the result of camlipixant binding within a vestibular site that is unique to P2X3, rather than to the P2X2/3 heteromer interfacial allosteric pocket bound by gefapixant [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 83.47
Molecular weight 458.46
XLogP 1.12
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CC2=NC(=C(C[C@H]3CN(CCO3)C(=O)OC)N2C=C1)C4=C(C=C(C=C4F)C(=O)NC)F
Isomeric SMILES CC1=CC2=NC(=C(N2C=C1)C[C@H]3CN(CCO3)C(=O)OC)C4=C(C=C(C=C4F)C(=O)NC)F
InChI InChI=1S/C23H24F2N4O4/c1-13-4-5-29-18(11-15-12-28(6-7-33-15)23(31)32-3)21(27-19(29)8-13)20-16(24)9-14(10-17(20)25)22(30)26-2/h4-5,8-10,15H,6-7,11-12H2,1-3H3,(H,26,30)/t15-/m0/s1
InChI Key SEHLMRJSQFAPCJ-HNNXBMFYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Camlipixant was being evaluated for antitussive efficacy in patients with refractory chronic cough, but development for this condition was terminated in mid-2026. A study in patients with irritable bowel syndrome (IBS) was continued at that time.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03979638 A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough Phase 2 Interventional Bellus Health Inc This trial was terminated early due to the impact of the COVID-19 pandemic on ability to complete recruitment. At the point of termination 68 patients with refractory chronic cough had been enrolled, and 52 had completed treatment.
NCT03638180 BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect Phase 1 Interventional Bellus Health Inc
NCT05600777 A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough Phase 3 Interventional Bellus Health Inc. - a GSK company
NCT05599191 A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough Phase 3 Interventional Bellus Health Inc. - a GSK company
NCT04693195 A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis Phase 2 Interventional Bellus Health Inc. - a GSK company
NCT07650084 A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension Phase 3 Interventional GlaxoSmithKline